For the treatment of lung cancer, Tecentriq plus chemotherapy is expected to become a first-line therapy
March 21, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Today, Genentech, a member of the Roche Group, announced that its Phase 3 clinical trial, IMpower131, has reached a common primary endpoint for progression-free survival (PFS), demonstrating that Tecentriq (atezolizumab) is combined with chemotherapy (carboplatin and ABRAXANE®). First-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) can reduce the risk of disease progression or death, and the effect is better than chemotherapy alone.
According to estimates by the American Cancer Society (ACS), more than 234,000 Americans will be diagnosed with lung cancer in 2018, with non-small cell lung cancer accounting for 85%. It is estimated that about 60% of lung cancers in the United States are diagnosed at an advanced stage. The prognosis of these patients is not optimistic, and new and effective treatments are urgently needed to alleviate the disease and prolong life.
Tecentriq is a heavyweight immunization drug for Genentech and is currently approved for treatment of urothelial carcinoma and NSCLC in the United States. It is an anti-PD-L1 monoclonal antibody that binds to PD-L1 on tumor cells and tumor-infiltrating immune cells, blocks its interaction with PD-1 and B7.1 receptors, and reactivates T cells. Kill cancer cells.
The IMpower131 was a phase 3 open-label, multicenter, randomized study evaluating Tecentriq binding to carboplatin and albumin-bound paclitaxel (nab-titosterol) or Tecentriq in combination with carboplatin and paclitaxel and chemotherapy alone The efficacy and safety of patients with stage IV squamous NSCLC who had not received chemotherapy before (carboplatin and nab-paclitaxel). The study enrolled 1021 patients randomized to receive a 1 : 1 ratio of 1) Tecentriq plus carboplatin and paclitaxel (group A); 2) Tecentriq plus carboplatin and nab-paclitaxel (group B); 3) Carboplatin and nab-paclitaxel (group C, control group). The primary primary endpoints of the study were 1) PFS as determined by the investigator in the intention-to-treat (ITT) population by RECIST v1.1 (Group B vs. Group C); and 2) Total survival determined in the ITT population (OS) ) (Group B vs. Group C). The results showed that the study reached the common primary endpoint of its PFS.
In addition, the safety of Tecentriq in combination with chemotherapy is consistent with the safety of known individual drugs, and no new safety signals have emerged.
“Squamous non-small cell lung cancer is difficult to treat, and there have been few new treatment options in the past few decades,†said Dr. Sandra Horning, Chief Medical Officer and Head of Global Product Development at Genentech. “We will share with global health regulators. The results of IMpower131 and look forward to seeing more mature overall lifetime data."
We hope that the combination therapy will continue to achieve good results in follow-up research and bring effective new treatments to lung cancer patients as soon as possible.
Reference materials:
[1] Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer
[2] Genentech's Tecentriq Shows Promise for First-line Lung Cancer Treatment
Disposable Paper Toilet Seat,Disposable Toilet Seat Covers,Disposable Sanitary Toilet Seat Cover,Disposable Paper Seat Cover
RFX+CARE Manufacturing Co.,Ltd. , https://www.rk-rfxcare.com